Harvard Bioscience (HBIO) Misses Q4 EPS by 10c

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.1 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Keefe, Bruyette & Woods Upgrades Nayax (NYAX) to Outperform
• Goldman Sachs Reinstates Etsy (ETSY) at Neutral